Form 4: Seres Therapeutics Director Stephen Berenson Granted New Stock Options

Seres Therapeutics, Inc. Director Stephen Berenson was granted 11,470 stock options with an exercise price of $10.71, vesting quarterly over one year.

Summary

• Stephen Berenson, a Director of Seres Therapeutics, Inc. (MCRB), was granted 11,470 stock options.
• The stock options have an exercise price of $10.71 per share.
• The options will vest and become exercisable in four equal quarterly installments.
• Vesting dates are scheduled for October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026.
• If the issuer's 2026 annual meeting of stockholders occurs before July 1, 2026, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting.
• Vesting is contingent upon Stephen Berenson continuing in service on the Board as a non-employee director through the applicable vesting date.
• The options have an expiration date of July 1, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not contain new financial performance data or strategic announcements that would significantly alter sentiment.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term performance and value creation.

Risks

• The vesting of the stock options is conditional upon Stephen Berenson's continued service as a non-employee director on the Board through each applicable vesting date.

Future Outlook

The grant of stock options with a multi-quarter vesting schedule indicates a continued alignment of the director's incentives with the company's long-term performance and shareholder value creation, contingent on their ongoing service.

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain experienced board members and align their interests with long-term company success.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule over one year with quarterly installments is a typical approach to ensure continued engagement and performance from board members.
• The exercise price being set at the market price on the grant date (implied by the Form 4 context) is also standard for incentive stock options.

Related Party Transactions

• Grant of 11,470 stock options to Stephen Berenson, a Director of Seres Therapeutics, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, as the value of the options is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest in four equal quarterly installments on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026 (or earlier if the 2026 annual meeting occurs before July 1, 2026).

Key Dates

Keywords

Seres Therapeutics, MCRB, Stock Option, Director, Equity Grant, Insider Transaction, Form 4, Compensation, Vesting